TITLE

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

AUTHOR(S)
Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R
PUB. DATE
September 2013
SOURCE
Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
ACCESSION #
89806864

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics